Home › All Companies › CGEM › Annual Report

Cullinan Therapeutics, Inc. (CGEM) — Annual Report

AI-Powered SEC Filing Analysis

← All CGEM filings
Latest Annual Report Filed: 2026-03-10

Key Insights

  • Cullinan Therapeutics is a biopharmaceutical company focused on developing novel oncology therapies. The company has a diversified pipeline of early-stage programs, including CLN-049, CLN-418, and Zipalertinib, which target various types of cancer.
  • The company has established several strategic collaborations, including an agreement with Adimab and a license agreement with Genrix Biopharmaceutical Co. Ltd. These partnerships provide opportunities for further development and potential revenue generation.
  • Cullinan Therapeutics has a strong financial position, with $XXX million in cash and investments as of December 31, 2025. However, the company continues to incur significant research and development expenses as it advances its pipeline.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-10. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Cullinan Therapeutics, Inc.

Quarterly Report Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.